The top 10 drugmakers of 2024

Big Pharma will get bigger, much bigger, over the next several years, with the companies vying to grow their sales in a range of established and emerging therapeutic areas, notably cancer and immunology.

Together, the top 10 drugmakers in 2024—as outlined in a recent report from EvaluatePharma—will hold 35% of the total biopharma market share, or more than $420 billion in sales that year.  

Novartis is slated to lead the pack, trailed by Pfizer, Roche, Johnson & Johnson and Sanofi in the top five. Among the top 10 drugmakers, EP predicts AstraZeneca and Bristol-Myers Squibb will grow their sales the most over the upcoming years, at 7% annually and 6% on average per year, respectively.

Over the next several years, analysts expect the drugmakers to shuffle positions somewhat from last year's sales rankings. AstraZeneca and BMS will each jump two spots, earning positions in the top 10. Novartis, J&J, Sanofi and GSK will each climb one spot, while analysts expect Pfizer to take one step from it's world-leading 2017 prescription sales.